GlaxoSmithKline plc : Director/PDMR Shareholding - Replacement

This announcement replaces the original announcement released on 3 January 2012 at 15.50 (RNS No: 9230U)

Due to an administrative error the change in one of the Non-Executive Director's interests in the American Depositary Shares (ADSs) of GlaxoSmithKline plc indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 3 January 2012.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £14.70 per Ordinary share and $45.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2011 to 30 December 2011:

Non Executive Director	Ordinary Shares	American Depositary Shares (ADSs)
Sir Christopher Gent	2,295.918
Prof. Sir Roy Anderson	573.980
Dr Stephanie Burns		325.294
Ms Stacey Cartwright	318.878
Mr Lawrence Culp		650.588
Sir Crispin Davis	2,125.850
Ms Judy Lewent		162.647*
Sir Deryck Maughan		650.588
Mr James Murdoch	1,275.510
Dr Daniel Podolsky		683.117
Mr Tom de Swaan	786.565
Sir Robert Wilson	573.980

The Company and the Non-Executive Directors were informed of these allocations on

3 January 2012.

This notification relates to transactions notified in accordance withDisclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

10 January 2012